Heart surgery sedative may cut confusion risk, massive study hints
NCT ID NCT07249164
First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
This study analyzed health records from over 400,000 adults who had heart surgery to see if the sedative dexmedetomidine helped prevent problems like confusion, kidney injury, or death within 30 days. Researchers compared patients who received the drug around surgery time to those who did not. The goal is to find better ways to manage sedation during routine heart surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
343,112 people
The number who actually took part.
- Started
-
Jan 2010
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients in the TriNetX Global Collaborative Network meeting the full CABG or valve eligibility criteria during 1 January 2010 through 1 July 2025 form the study population before propensity-score matching. CABG is primary and valve exploratory, with separate procedure anchors and matching. Age at Event is 18-100 years, subject to platform privacy restrictions, with the same five-domain HCO filter. The 9 September 2026 counts were 235,752 CABG, 139,542 valve and 32,182 meeting both complete definitions. Enrollment is the overlap-adjusted platform total: 235,752 + 139,542 - 32,182 = 343,112. This is a derived count from sequential LIVE queries, not a certified fixed-time snapshot or independently verified cross-HCO person deduplication. Matched and endpoint denominators are reported separately; effects are not pooled.
- Ages
-
18 to 100 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A qualifying CABG-coded procedure for the primary analysis, or a qualifying valve-coded procedure for the separate exploratory analysis, during 1 January 2010 through 1 July 2025. * Age at Event 18-100 at a qualifying procedure, subject to the platform's additional age-related privacy restrictions. * A procedure-date index defined by the first qualifying procedure within the clinical period after the date and age filters, with the same eligibility logic in both exposure groups within each procedure population. * Data contributed by healthcare organisations providing demographics, diagnoses, procedures, medications and laboratory domains. * Medication-record status classified using RxNorm 48937 during days -1 through 0 relative to the qualifying index procedure. Exclusion Criteria: * An ESRD or dialysis record during days -90 through -1: ICD-10-CM N18.6, Z49 or Z99.2; SNOMED CT 265764009; ICD-10-PCS 5A1D60Z or 5A1D00Z; or ICD-9-CM 39.95. * Any R41.0 or F05 record on or before day 0 in all available prior history relative to the index procedure, applied before matching in both the CABG-coded and valve-coded populations. Primary, secondary, F05-only and encounter endpoints retain this eligibility definition. Native matching is repeated within each outcome batch, and identical matched patients across batches are not established. Some eligibility records may occur after the exposure window begins on day -1, which may introduce selection or collider bias despite application before matching. The study does not require continuous preoperative observation, complete 30-day follow-up or survival to a landmark. Missing laboratory measurements do not automatically exclude a patient. The available aggregate outputs do not permit clinical adjudication of individual procedures or confirmation that surgery is first-ever or isolated.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiac surgical procedures are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
China Medical University Hospital
Taichung, Taichung City, 40447, Taiwan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Heart bypass surgeons test which vein layout keeps grafts open
- A soft patch that watches your heart beat in real time
- Zapping the ear: a new way to stop Post-Surgery heart rhythm problems?
- Squeeze a ball, lower your blood pressure? heart trial puts handgrip exercise to the test
- New heart scan aims to spot hidden plaque before it strikes
- A standard IV fluid dose may reveal who is at risk after bowel surgery